Goldman Sachs Group Inc. trimmed its stake in Arbutus Biopharma Corporation (NASDAQ:ABUS) by 62.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,706 shares of the biopharmaceutical company’s stock after selling 149,970 shares during the period. Goldman Sachs Group Inc. owned about 0.17% of Arbutus Biopharma Corporation worth $330,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ABUS. Bank of Montreal Can boosted its position in shares of Arbutus Biopharma Corporation by 1.9% during the 2nd quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock valued at $3,147,000 after acquiring an additional 16,535 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Arbutus Biopharma Corporation during the 2nd quarter valued at about $478,000. Renaissance Technologies LLC boosted its position in shares of Arbutus Biopharma Corporation by 785.1% during the 1st quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock valued at $405,000 after acquiring an additional 110,499 shares in the last quarter. OxFORD Asset Management LLP boosted its position in shares of Arbutus Biopharma Corporation by 89.9% during the 2nd quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after acquiring an additional 39,436 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Arbutus Biopharma Corporation by 2.7% during the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 2,035 shares in the last quarter. Institutional investors own 66.93% of the company’s stock.

Several brokerages have recently weighed in on ABUS. ValuEngine lowered shares of Arbutus Biopharma Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Zacks Investment Research upgraded shares of Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, November 7th. Leerink Swann reiterated a “market perform” rating and set a $5.00 target price (up from $4.00) on shares of Arbutus Biopharma Corporation in a research report on Tuesday, November 7th. JMP Securities reiterated an “outperform” rating and set a $13.00 target price (up from $12.00) on shares of Arbutus Biopharma Corporation in a research report on Wednesday, October 4th. Finally, Wedbush reiterated an “outperform” rating and set a $9.00 target price on shares of Arbutus Biopharma Corporation in a research report on Wednesday, September 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $13.00.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/11/17/arbutus-biopharma-corporation-abus-shares-sold-by-goldman-sachs-group-inc.html.

Arbutus Biopharma Corporation (NASDAQ:ABUS) opened at $5.85 on Friday. Arbutus Biopharma Corporation has a 1-year low of $2.35 and a 1-year high of $8.25. The company has a debt-to-equity ratio of 0.08, a current ratio of 11.03 and a quick ratio of 11.03.

In related news, insider Michael J. Sofia sold 10,000 shares of Arbutus Biopharma Corporation stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $8.00, for a total transaction of $80,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 10.00% of the company’s stock.

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Want to see what other hedge funds are holding ABUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arbutus Biopharma Corporation (NASDAQ:ABUS).

Institutional Ownership by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Receive News & Stock Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related stocks with our FREE daily email newsletter.